Email Updates

You are here

Home»Trial Summary Table

Trial Summary Table

Trial Name Phase Start Date Sponsors Countries Population Candidate(s) Status Expected Completion Date
HPTN 076 II Friday, October 31, 2014 PATH, Bill and Melinda Gates Foundation, NIAID, NIH United States of America, South Africa, Zimbabwe Women TMC 278 Completed October 2017
HPTN 077 II Sunday, February 1, 2015 National Institute of Allergy and Infectious Diseases (NIAID) United States of America, Brazil, Malawi, South Africa Women, Men Cabotegravir (GSK 744) Completed July 2017
HPTN 082 Demo Project Wednesday, June 1, 2016 Wits RHI, HPTN; DAIDS, NIAID, NIMH South Africa, Zimbabwe Women TDF/FTC (Truvada) Completed August 2018
HPTN 083 III, IIb Tuesday, December 20, 2016 NIAID, Viiv Healthcare, Gilead United States of America, Thailand, Argentina, Peru, India, Vietnam, Brazil, South Africa MSM Cabotegravir (GSK 744), TDF/FTC (Truvada) Stopped Early March 2022
HPTN 084 III Monday, October 23, 2017 NIAID (DAIDS-ES: 38070), Viiv Healthcare, Gilead Botswana, Kenya, South Africa, Uganda, Zimbabwe, Swaziland, Malawi Women Cabotegravir (GSK 744), TDF/FTC (Truvada), F/TDF Stopped Early May 2022
HPTN 091 Open Label Sunday, March 21, 2021 HPTN, Gilead United States of America, Brazil Men TAF/FTC (Descovy), TDF/FTC (Truvada) November 2024
HPTN 094/ INTEGRA Demo Project, Open Label Wednesday, June 9, 2021 NIAID (DAIDS ID: 38715) United States of America HIV positive, Injecting drug users, Men, Women Ongoing
HPTN 096 Open Label, Other Friday, April 1, 2022 HPTN; DIAID, NAID HIV positive, MSM Ongoing June 2027
HVTN 141/ HPTN 105 Open Label Wednesday, March 1, 2023 Men, Women March 2024
IMPAACT 2009 (DAIDS ID 30020) Demo Project International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network Zimbabwe, Uganda, South Africa, Malawi Women Planned

Pages